The role of prostaglandins (PGs) in hypertension (HT) is reviewed, emphasising their biochemical characteristics, physiological effects and functions, especially in the cardiovascular area, and the current evidence of their participation in the antihypertensive activity of a
Prostaglandins (PGs) are autacoids and a reactive product of membrane phospholipids produced normally by many cell types, including endothelial cells and part of the eicosanoids related to dietary essential fatty acids (FA). They have many functions ranging from cardiovascular, renal, gastrointestinal, and haemostatic control to the reproductive biology, including their important role in the inflammatory process, [1] [2] [3] and are highly influential in several physiological, pharmacological, pathological, and therapeutic aspects of animal and human organs and tissue function that ought to be analysed from the past, present and future. In human tissues arachidonic acid (AA) is their more abundant precursor ( Figure 1 ) coming from foods linoleic acid and the eicosapentanoic 5,8,11,14,17 acid from some cold marine water fish oil. 4, 5 At least four PGs have been identified in human tissues with multiple effects and functions depending upon their receptors: PGE 2 PGF 2␣ PGI 2 (prostacyclin) and TXA 2 (thromboxane) (Figure 1 ).
Since the discovery of the hypotensive effect of dogs and man's male accessory sexual glands 6, 7 and the hypotensive effect of human urine 8 at the beginning of the century, and later the methods of detecting and measuring them, an extensive search for information regarding a role in biological process produced valuable data strongly suggesting that the kidney is important not only as a target organ of hypertension (HT) but also as an organ that may either cause it or produce an antihypertensive mechanism. 9 Two PGs-secreting tumors that lowered blood pressure were reported, 10, 11 suggesting the kidneys to be involved in their metabolism ( Figure 1 ) at several sites such as the medulla and mesangium 9, 12 excreting their metabolites into urine where it can be detected, as well as in practically every body tissue, so that it has contributed to clarify their role, producing such important knowledge to medicine that it provided reasons for the granting Such a broad distribution has framed them as local hormones (since they are inactivated by the lungs 14 ) and the intensive chemical and biochemical work recently developed provided new developments pointing out their properties, multiple relationships, usefulness and pathophysiological characteristics.
(1) Development of the first generation of parenteral, oral and topic PGs therapeutic agents in obstetrics and gynecology, the gastrointestinal system and as antihypertensive drugs. 9, 15, 16 (2) The so-called 'nephroprotection', where renal blood flow (RBF) is redistributed and improved in association with other renal vasoactive agents 12,17-22 that will be detailed elsewhere in this supplement. (3) Modulation of several other vasoactive agents, with a complex hormonal interaction: the kallikrein-kinin system, nitric oxide (NO), atrial natriuretic peptide, renin-angiotensin system, catecholamines, and endothelins, so that it has led to clarify the mechanism of action of some drugs and pathophysiological mechanisms. Renal pressure-natriuresis, peripheral vascular resistance and the central nervous barostat are three loci where long-term regulation of blood pressure is probably controlled, conforming a perfect balance between the vasoconstrictor and vasodilator mechanisms through many interactions 9, 12, 18, 23, 24 that once broken, either a hypertensive or hypotensive state may occur. Of all those activities, probably the most extensively studied in the last 15 years is their capacity to either stimulate or depress the smooth muscle activity leading to the reproductive and cardiovascular control. Thus, several reports indicate their important role in the normal blood pressure regulation mechanisms and they may be involved in electrolyte balance. 25 For instance, the blockade of bradykinin breakdown and enhancement of PGs release probably participate in the antihypertensive effect of ACE inhibi- tors 17, [26] [27] [28] (Figure 2) , diuretic therapy at long range, 29 calcium channel-blocking agents and angiotensin II receptor blockers (AT 1 blockade) 9, 19, 30, 31 among others, as well as the pathogenic mechanism of some diseases such as acute nephritic syndrome where ACEIs are beneficial by increasing bradykinin and PGs survival. 32, 33 Obesity and diabetes are marked by increased incidence of hypertension (HT), and elevated levels of FA or their P 450 oxygenated metabolites may contribute to this association. 23 It is now appreciated that NO, a reactive oxidation product of nitrogen, is produced normally by many cell types, including endothelial cells, and has functions ranging from neurotransmission to vasodilation; also, there is a complex association between PGs, NO, and cytokine pointing to the regulation of the inflammatory process: proinflammatory cytokine interleukin-1␤ (IL) stimulates inducible nitric oxide synthase (iNOS) mRNA, protein, and NO production in neonatal ventricular myocytes 34 and, in other types of cells, it also activates phospolipase A 2 , which liberates AA (Figure 1 ), but it also induces the cyclo-oxygenase isoform (COX), 17 and NO has been shown to directly stimulate COX activity and AA metabolites other than COX products, possibly being products of the lipoxygenase pathway, which are involved in IL regulation of iNOS 17 ( Figure 1 ). Moreover, it has been suggested that the renal vasoconstriction and antinatriuretic effects induced by a prolonged infusion of a COX inhibition are significantly enhanced when NO synthesis is blocked; 20 additionally, a chronic NO inhibition may contribute to systemic HT and play a pivotal role in the development of renal structural injury. Finally, the association of NO-PGs contributes to the regulation of RBF and renal funcJournal of Human Hypertension tion and structure, suggesting that both NO and PGs control a similar percentage or rat renal papillary blood flow, but NO seems to be more important than PGs as a mediator of the pressure-blood flow relationship; 21, 30, 34 also, a relationship between bradykinin receptors and PGs has been suggested, and they have a steroidogenic effect. 30, 35 (4) Induction of arterial vasodilation is the logical approach to optimal treatment of the increased peripheral resistance observed in essential HT. Although the ideal antihypertensive drug is not yet available, PGs do comply with many of the requirements to qualify, therefore it is mandatory to keep on looking for such a compound in the PGs area. Thus, the decreased urinary excretion of the vasodilator PGE 2 and PGI 2 in experimental and human hypertensive states 24, 32, 36 may explain its importance as antihypertensives in the balance proposed. On the contrary, elevated PGs or their administration have been associated to low blood pressure or an antihypertensive effect. 10, 11, 16, 18, 24, 29, [37] [38] [39] However, its potential beneficial antihypertensive and oxytocic effect has been obscured by its strong stimulant effect on the guts smooth muscle. (5) The interesting and important clinical fact of the negative interaction between HT, antihypertensive treatment and non-steroidal anti-inflammatory drugs (NSAIDs). 3, 19 However, a meta-analysis of reports showing that blood pressure may rise during treatment with these drugs indicate the rise in mean blood pressure is relatively small and whether such an increment of blood pressure following the administraton of NSAIDs is sustained over time has not been clearly established. Sulindac and aspirin itself seem to be the less troublesome. Interrelationships among the three renal vasoactive systems. This integrated polyenzymatic system regulates blood pressure and hydromineral metabolism in the kidney, in a balance between the antihypertensive and prohypertensive mechanisms involving the prostaglandins. 1,2 and 3 are the substrates for each system. COX-2 = Cyclooxygenase 2. PGE 2 and calidin are the main renal prostaglandin and kinin respectively. Kininase II and converting enzyme is the same enzyme with two different effects, leading normally to increased blood pressure in case it is decreased, because it induces the formation of the prohypertensive angiotensin-aldosterone system, and at the same time catabolizes the kinins to inactive peptides, thereby blunting the antihypertensive mechanism. The finding of the angiotensin converting enzyme inhibitors (ACEI) drugs, which act as vasodilator by a double mechanism of inhibiting the prohypertensive mechanism and increasing the survival of the kallikrein-kinins system which in turn leads to augmented availability of prostaglandins, all of which had led to significant benefit to the hypertensive population. 15 (9) The important role in the haemostatic process since they produce a balance between the endothelial PGI 2 and the platelets TXA 2 .
9,40 (10) PGs have emerged as a therapeutic option for patients with peripheral vascular disease, as well as pulmonary hypertension as a means to increase blood flow. 41 (11) Normal pregnancy and pregnancy-induced HT deserve an important chapter. The role of decreased PGE 2 and PGF 2␣ and increased TXA 2 (and/or its precursors) and endothelins in plasma, urine, placenta and even platelets has gained importance in the pathogenesis of HT and altered renal function that accompanies pre-eclampsia. 21, 35, [42] [43] [44] [45] In summary, PGs play a conspicuous role in many body functions, blood pressure regulation being among the most studied. Their widespread distribution, multiple effects, and interactions make them sufficiently attractive to be considered as meaningful in the pathogenic, diagnosis and therapy of several types of human HT, avoiding the risk of oversimplification of their role and actions.
